nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—Dactinomycin—muscle cancer	0.275	0.34	CbGbCtD
Neostigmine—ABCB1—Vincristine—muscle cancer	0.169	0.21	CbGbCtD
Neostigmine—ABCB1—Etoposide—muscle cancer	0.155	0.192	CbGbCtD
Neostigmine—ABCB1—Doxorubicin—muscle cancer	0.106	0.131	CbGbCtD
Neostigmine—ABCB1—Methotrexate—muscle cancer	0.103	0.127	CbGbCtD
Neostigmine—BCHE—diaphragm—muscle cancer	0.0145	0.529	CbGeAlD
Neostigmine—Abdominal cramps—Vincristine—muscle cancer	0.00515	0.0313	CcSEcCtD
Neostigmine—Paralysis—Vincristine—muscle cancer	0.005	0.0304	CcSEcCtD
Neostigmine—Nystagmus—Vincristine—muscle cancer	0.00486	0.0296	CcSEcCtD
Neostigmine—Cardiovascular disorder—Etoposide—muscle cancer	0.0032	0.0195	CcSEcCtD
Neostigmine—Chest discomfort—Etoposide—muscle cancer	0.00318	0.0193	CcSEcCtD
Neostigmine—Coma—Vincristine—muscle cancer	0.00317	0.0193	CcSEcCtD
Neostigmine—Lacrimation—Doxorubicin—muscle cancer	0.00248	0.0151	CcSEcCtD
Neostigmine—Paralysis—Methotrexate—muscle cancer	0.00243	0.0148	CcSEcCtD
Neostigmine—Cardiac arrest—Vincristine—muscle cancer	0.0024	0.0146	CcSEcCtD
Neostigmine—Paralysis—Doxorubicin—muscle cancer	0.0021	0.0128	CcSEcCtD
Neostigmine—Nystagmus—Doxorubicin—muscle cancer	0.00204	0.0124	CcSEcCtD
Neostigmine—ACHE—tendon—muscle cancer	0.00204	0.0743	CbGeAlD
Neostigmine—Cardiac arrest—Etoposide—muscle cancer	0.00194	0.0118	CcSEcCtD
Neostigmine—Cramp muscle—Etoposide—muscle cancer	0.00184	0.0112	CcSEcCtD
Neostigmine—Flushing—Dactinomycin—muscle cancer	0.00181	0.011	CcSEcCtD
Neostigmine—Dysarthria—Methotrexate—muscle cancer	0.00178	0.0108	CcSEcCtD
Neostigmine—Bronchospasm—Etoposide—muscle cancer	0.00174	0.0106	CcSEcCtD
Neostigmine—Urinary tract disorder—Vincristine—muscle cancer	0.00172	0.0105	CcSEcCtD
Neostigmine—Sweating increased—Etoposide—muscle cancer	0.00172	0.0105	CcSEcCtD
Neostigmine—Connective tissue disorder—Vincristine—muscle cancer	0.00171	0.0104	CcSEcCtD
Neostigmine—Urethral disorder—Vincristine—muscle cancer	0.00171	0.0104	CcSEcCtD
Neostigmine—ACHE—testis—muscle cancer	0.00169	0.0616	CbGeAlD
Neostigmine—Cardiovascular disorder—Doxorubicin—muscle cancer	0.00166	0.0101	CcSEcCtD
Neostigmine—Lacrimation increased—Doxorubicin—muscle cancer	0.00158	0.00963	CcSEcCtD
Neostigmine—Mediastinal disorder—Vincristine—muscle cancer	0.00157	0.00956	CcSEcCtD
Neostigmine—Dysarthria—Doxorubicin—muscle cancer	0.00154	0.00938	CcSEcCtD
Neostigmine—Coma—Methotrexate—muscle cancer	0.00154	0.00937	CcSEcCtD
Neostigmine—Mental disorder—Vincristine—muscle cancer	0.00153	0.00929	CcSEcCtD
Neostigmine—Atrioventricular block—Doxorubicin—muscle cancer	0.0015	0.00915	CcSEcCtD
Neostigmine—Salivary hypersecretion—Doxorubicin—muscle cancer	0.00142	0.00862	CcSEcCtD
Neostigmine—Urinary tract disorder—Etoposide—muscle cancer	0.0014	0.00849	CcSEcCtD
Neostigmine—Agitation—Vincristine—muscle cancer	0.0014	0.00849	CcSEcCtD
Neostigmine—Urethral disorder—Etoposide—muscle cancer	0.00139	0.00842	CcSEcCtD
Neostigmine—BCHE—smooth muscle tissue—muscle cancer	0.00134	0.0486	CbGeAlD
Neostigmine—Coma—Doxorubicin—muscle cancer	0.00133	0.00811	CcSEcCtD
Neostigmine—Convulsion—Vincristine—muscle cancer	0.00132	0.008	CcSEcCtD
Neostigmine—Flushing—Etoposide—muscle cancer	0.00131	0.00798	CcSEcCtD
Neostigmine—Mediastinal disorder—Etoposide—muscle cancer	0.00127	0.00775	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00126	0.00769	CcSEcCtD
Neostigmine—Anaphylactic shock—Vincristine—muscle cancer	0.00124	0.00754	CcSEcCtD
Neostigmine—Osteoarthritis—Methotrexate—muscle cancer	0.00122	0.00744	CcSEcCtD
Neostigmine—Nervous system disorder—Vincristine—muscle cancer	0.00122	0.00739	CcSEcCtD
Neostigmine—Hyperhidrosis—Vincristine—muscle cancer	0.0012	0.00729	CcSEcCtD
Neostigmine—Muscle spasms—Etoposide—muscle cancer	0.00118	0.00719	CcSEcCtD
Neostigmine—Hypotension—Vincristine—muscle cancer	0.00116	0.00704	CcSEcCtD
Neostigmine—BCHE—cardiac atrium—muscle cancer	0.00115	0.0419	CbGeAlD
Neostigmine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00113	0.0069	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00113	0.00687	CcSEcCtD
Neostigmine—Insomnia—Vincristine—muscle cancer	0.00112	0.00682	CcSEcCtD
Neostigmine—Abdominal pain—Dactinomycin—muscle cancer	0.0011	0.00667	CcSEcCtD
Neostigmine—Loss of consciousness—Etoposide—muscle cancer	0.00108	0.00658	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00107	0.00651	CcSEcCtD
Neostigmine—Convulsion—Etoposide—muscle cancer	0.00107	0.00648	CcSEcCtD
Neostigmine—Osteoarthritis—Doxorubicin—muscle cancer	0.00106	0.00644	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00104	0.00633	CcSEcCtD
Neostigmine—Hypersensitivity—Dactinomycin—muscle cancer	0.00102	0.00622	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vincristine—muscle cancer	0.00101	0.00616	CcSEcCtD
Neostigmine—Cardiac arrest—Doxorubicin—muscle cancer	0.00101	0.00613	CcSEcCtD
Neostigmine—Anaphylactic shock—Etoposide—muscle cancer	0.001	0.00611	CcSEcCtD
Neostigmine—Asthenia—Dactinomycin—muscle cancer	0.000995	0.00605	CcSEcCtD
Neostigmine—Tachycardia—Etoposide—muscle cancer	0.00098	0.00596	CcSEcCtD
Neostigmine—Abdominal pain—Vincristine—muscle cancer	0.00098	0.00596	CcSEcCtD
Neostigmine—Skin disorder—Etoposide—muscle cancer	0.000975	0.00593	CcSEcCtD
Neostigmine—BCHE—bone marrow—muscle cancer	0.000972	0.0354	CbGeAlD
Neostigmine—Hyperhidrosis—Etoposide—muscle cancer	0.000971	0.0059	CcSEcCtD
Neostigmine—Diarrhoea—Dactinomycin—muscle cancer	0.000949	0.00577	CcSEcCtD
Neostigmine—Drowsiness—Methotrexate—muscle cancer	0.000943	0.00573	CcSEcCtD
Neostigmine—Hypotension—Etoposide—muscle cancer	0.000938	0.00571	CcSEcCtD
Neostigmine—BCHE—vagina—muscle cancer	0.000931	0.0339	CbGeAlD
Neostigmine—Hypersensitivity—Vincristine—muscle cancer	0.000913	0.00555	CcSEcCtD
Neostigmine—Dyspnoea—Etoposide—muscle cancer	0.000895	0.00544	CcSEcCtD
Neostigmine—Somnolence—Etoposide—muscle cancer	0.000893	0.00543	CcSEcCtD
Neostigmine—Asthenia—Vincristine—muscle cancer	0.000889	0.00541	CcSEcCtD
Neostigmine—Vomiting—Dactinomycin—muscle cancer	0.000882	0.00536	CcSEcCtD
Neostigmine—Rash—Dactinomycin—muscle cancer	0.000875	0.00532	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000867	0.00527	CcSEcCtD
Neostigmine—BCHE—head—muscle cancer	0.00086	0.0313	CbGeAlD
Neostigmine—Diarrhoea—Vincristine—muscle cancer	0.000848	0.00516	CcSEcCtD
Neostigmine—Pollakiuria—Doxorubicin—muscle cancer	0.000846	0.00514	CcSEcCtD
Neostigmine—Urinary tract disorder—Methotrexate—muscle cancer	0.000836	0.00508	CcSEcCtD
Neostigmine—BCHE—testis—muscle cancer	0.000831	0.0303	CbGeAlD
Neostigmine—Urethral disorder—Methotrexate—muscle cancer	0.00083	0.00505	CcSEcCtD
Neostigmine—Nausea—Dactinomycin—muscle cancer	0.000824	0.00501	CcSEcCtD
Neostigmine—Gastrointestinal pain—Etoposide—muscle cancer	0.000821	0.00499	CcSEcCtD
Neostigmine—Dizziness—Vincristine—muscle cancer	0.00082	0.00498	CcSEcCtD
Neostigmine—Drowsiness—Doxorubicin—muscle cancer	0.000817	0.00497	CcSEcCtD
Neostigmine—ABCB1—embryo—muscle cancer	0.000809	0.0295	CbGeAlD
Neostigmine—Urticaria—Etoposide—muscle cancer	0.000798	0.00485	CcSEcCtD
Neostigmine—Abdominal pain—Etoposide—muscle cancer	0.000794	0.00483	CcSEcCtD
Neostigmine—Vomiting—Vincristine—muscle cancer	0.000788	0.00479	CcSEcCtD
Neostigmine—Rash—Vincristine—muscle cancer	0.000782	0.00475	CcSEcCtD
Neostigmine—Dermatitis—Vincristine—muscle cancer	0.000781	0.00475	CcSEcCtD
Neostigmine—Headache—Vincristine—muscle cancer	0.000777	0.00472	CcSEcCtD
Neostigmine—Mediastinal disorder—Methotrexate—muscle cancer	0.000763	0.00464	CcSEcCtD
Neostigmine—Bradycardia—Doxorubicin—muscle cancer	0.000746	0.00454	CcSEcCtD
Neostigmine—Mental disorder—Methotrexate—muscle cancer	0.000742	0.00451	CcSEcCtD
Neostigmine—Hypersensitivity—Etoposide—muscle cancer	0.00074	0.0045	CcSEcCtD
Neostigmine—Nausea—Vincristine—muscle cancer	0.000736	0.00448	CcSEcCtD
Neostigmine—Urinary tract disorder—Doxorubicin—muscle cancer	0.000724	0.0044	CcSEcCtD
Neostigmine—Asthenia—Etoposide—muscle cancer	0.00072	0.00438	CcSEcCtD
Neostigmine—Connective tissue disorder—Doxorubicin—muscle cancer	0.00072	0.00438	CcSEcCtD
Neostigmine—Urethral disorder—Doxorubicin—muscle cancer	0.000719	0.00437	CcSEcCtD
Neostigmine—Pruritus—Etoposide—muscle cancer	0.00071	0.00432	CcSEcCtD
Neostigmine—Diarrhoea—Etoposide—muscle cancer	0.000687	0.00418	CcSEcCtD
Neostigmine—Flushing—Doxorubicin—muscle cancer	0.00068	0.00414	CcSEcCtD
Neostigmine—Dizziness—Etoposide—muscle cancer	0.000664	0.00404	CcSEcCtD
Neostigmine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000661	0.00402	CcSEcCtD
Neostigmine—Arrhythmia—Doxorubicin—muscle cancer	0.000655	0.00398	CcSEcCtD
Neostigmine—Mental disorder—Doxorubicin—muscle cancer	0.000642	0.00391	CcSEcCtD
Neostigmine—Convulsion—Methotrexate—muscle cancer	0.000639	0.00388	CcSEcCtD
Neostigmine—Vomiting—Etoposide—muscle cancer	0.000638	0.00388	CcSEcCtD
Neostigmine—Rash—Etoposide—muscle cancer	0.000633	0.00385	CcSEcCtD
Neostigmine—Dermatitis—Etoposide—muscle cancer	0.000633	0.00385	CcSEcCtD
Neostigmine—Headache—Etoposide—muscle cancer	0.000629	0.00382	CcSEcCtD
Neostigmine—Flatulence—Doxorubicin—muscle cancer	0.000629	0.00382	CcSEcCtD
Neostigmine—Arthralgia—Methotrexate—muscle cancer	0.000627	0.00382	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000623	0.00379	CcSEcCtD
Neostigmine—Muscle spasms—Doxorubicin—muscle cancer	0.000614	0.00373	CcSEcCtD
Neostigmine—ABCB1—renal system—muscle cancer	0.000612	0.0223	CbGeAlD
Neostigmine—Anaphylactic shock—Methotrexate—muscle cancer	0.000601	0.00366	CcSEcCtD
Neostigmine—Nausea—Etoposide—muscle cancer	0.000596	0.00363	CcSEcCtD
Neostigmine—Nervous system disorder—Methotrexate—muscle cancer	0.00059	0.00359	CcSEcCtD
Neostigmine—Agitation—Doxorubicin—muscle cancer	0.000586	0.00357	CcSEcCtD
Neostigmine—Skin disorder—Methotrexate—muscle cancer	0.000584	0.00355	CcSEcCtD
Neostigmine—Hyperhidrosis—Methotrexate—muscle cancer	0.000581	0.00354	CcSEcCtD
Neostigmine—Syncope—Doxorubicin—muscle cancer	0.000572	0.00348	CcSEcCtD
Neostigmine—Hypotension—Methotrexate—muscle cancer	0.000562	0.00342	CcSEcCtD
Neostigmine—Loss of consciousness—Doxorubicin—muscle cancer	0.000561	0.00341	CcSEcCtD
Neostigmine—Convulsion—Doxorubicin—muscle cancer	0.000553	0.00336	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000548	0.00333	CcSEcCtD
Neostigmine—Insomnia—Methotrexate—muscle cancer	0.000544	0.00331	CcSEcCtD
Neostigmine—Arthralgia—Doxorubicin—muscle cancer	0.000543	0.0033	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00054	0.00328	CcSEcCtD
Neostigmine—Dyspnoea—Methotrexate—muscle cancer	0.000536	0.00326	CcSEcCtD
Neostigmine—Somnolence—Methotrexate—muscle cancer	0.000535	0.00325	CcSEcCtD
Neostigmine—Dry mouth—Doxorubicin—muscle cancer	0.000531	0.00323	CcSEcCtD
Neostigmine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000521	0.00317	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000519	0.00316	CcSEcCtD
Neostigmine—Shock—Doxorubicin—muscle cancer	0.000512	0.00312	CcSEcCtD
Neostigmine—Nervous system disorder—Doxorubicin—muscle cancer	0.000511	0.00311	CcSEcCtD
Neostigmine—Tachycardia—Doxorubicin—muscle cancer	0.000508	0.00309	CcSEcCtD
Neostigmine—Skin disorder—Doxorubicin—muscle cancer	0.000506	0.00308	CcSEcCtD
Neostigmine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000503	0.00306	CcSEcCtD
Neostigmine—Gastrointestinal pain—Methotrexate—muscle cancer	0.000492	0.00299	CcSEcCtD
Neostigmine—Hypotension—Doxorubicin—muscle cancer	0.000487	0.00296	CcSEcCtD
Neostigmine—Urticaria—Methotrexate—muscle cancer	0.000478	0.00291	CcSEcCtD
Neostigmine—Abdominal pain—Methotrexate—muscle cancer	0.000475	0.00289	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000475	0.00289	CcSEcCtD
Neostigmine—Insomnia—Doxorubicin—muscle cancer	0.000471	0.00286	CcSEcCtD
Neostigmine—Dyspnoea—Doxorubicin—muscle cancer	0.000464	0.00282	CcSEcCtD
Neostigmine—ABCB1—bone marrow—muscle cancer	0.000463	0.0169	CbGeAlD
Neostigmine—Somnolence—Doxorubicin—muscle cancer	0.000463	0.00282	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00045	0.00273	CcSEcCtD
Neostigmine—ABCB1—vagina—muscle cancer	0.000444	0.0162	CbGeAlD
Neostigmine—Hypersensitivity—Methotrexate—muscle cancer	0.000443	0.00269	CcSEcCtD
Neostigmine—Asthenia—Methotrexate—muscle cancer	0.000432	0.00262	CcSEcCtD
Neostigmine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000426	0.00259	CcSEcCtD
Neostigmine—Pruritus—Methotrexate—muscle cancer	0.000426	0.00259	CcSEcCtD
Neostigmine—Urticaria—Doxorubicin—muscle cancer	0.000414	0.00252	CcSEcCtD
Neostigmine—Abdominal pain—Doxorubicin—muscle cancer	0.000412	0.0025	CcSEcCtD
Neostigmine—Diarrhoea—Methotrexate—muscle cancer	0.000412	0.0025	CcSEcCtD
Neostigmine—ABCB1—head—muscle cancer	0.00041	0.0149	CbGeAlD
Neostigmine—Dizziness—Methotrexate—muscle cancer	0.000398	0.00242	CcSEcCtD
Neostigmine—ABCB1—testis—muscle cancer	0.000396	0.0144	CbGeAlD
Neostigmine—Hypersensitivity—Doxorubicin—muscle cancer	0.000384	0.00233	CcSEcCtD
Neostigmine—Vomiting—Methotrexate—muscle cancer	0.000382	0.00233	CcSEcCtD
Neostigmine—Rash—Methotrexate—muscle cancer	0.000379	0.00231	CcSEcCtD
Neostigmine—Dermatitis—Methotrexate—muscle cancer	0.000379	0.0023	CcSEcCtD
Neostigmine—Headache—Methotrexate—muscle cancer	0.000377	0.00229	CcSEcCtD
Neostigmine—Asthenia—Doxorubicin—muscle cancer	0.000374	0.00227	CcSEcCtD
Neostigmine—Pruritus—Doxorubicin—muscle cancer	0.000368	0.00224	CcSEcCtD
Neostigmine—Nausea—Methotrexate—muscle cancer	0.000357	0.00217	CcSEcCtD
Neostigmine—Diarrhoea—Doxorubicin—muscle cancer	0.000356	0.00217	CcSEcCtD
Neostigmine—Dizziness—Doxorubicin—muscle cancer	0.000344	0.00209	CcSEcCtD
Neostigmine—Vomiting—Doxorubicin—muscle cancer	0.000331	0.00201	CcSEcCtD
Neostigmine—Rash—Doxorubicin—muscle cancer	0.000328	0.002	CcSEcCtD
Neostigmine—Dermatitis—Doxorubicin—muscle cancer	0.000328	0.00199	CcSEcCtD
Neostigmine—Headache—Doxorubicin—muscle cancer	0.000326	0.00198	CcSEcCtD
Neostigmine—Nausea—Doxorubicin—muscle cancer	0.000309	0.00188	CcSEcCtD
